References
- Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993; 90:720 - 4; http://dx.doi.org/10.1073/pnas.90.2.720; PMID: 8421711
- Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116:4099 - 102; http://dx.doi.org/10.1182/blood-2010-04-281931; PMID: 20668228
- Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725 - 33; http://dx.doi.org/10.1056/NEJMoa1103849; PMID: 21830940
- Rosenberg SA, Kochenderfer JN. Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. Mol Ther 2011; 19:1928 - 30; http://dx.doi.org/10.1038/mt.2011.223; PMID: 22051601
- Urbanska K, Lanitis E, Poussin M, Lynn R, Gavin BP, Kelderman S, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor. [Epub ahead of print] Cancer Res 2012; http://dx.doi.org/10.1158/0008-5472.CAN-11-3890; PMID: 22315351
- Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Lett 2007; 255:263 - 74; http://dx.doi.org/10.1016/j.canlet.2007.04.012; PMID: 17560019
- Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor. [Epub ahead of print] Mol Ther 2011; http://dx.doi.org/10.1038/mt.2011.256; PMID: 22127019
- Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84:3261 - 82; PMID: 7524733
- Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B, et al. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents “veto” apoptosis of antibody-targeted cytotoxic T cells. Blood 1998; 92:4750 - 7; PMID: 9845541
- Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 2011; 118:975 - 83; http://dx.doi.org/10.1182/blood-2011-02-334284; PMID: 21653325